RefleXion’s biology-guided radiotherapy (BgRT) allows us to detect and respond to signals emitted from the cancer itself, and for the first time, use them to guide immediate treatment.
When PET radiotracers are introduced into the body, cancer absorbs them and acts as a biological beacon, which our machine can use to track and treat cancer in real time.
Learn More About Emissions
Our technology aims to deliver high doses of radiation to tumors, even while in motion, for greater impact to the tumor with less dose to the surrounding tissue.
Learn About Targeting
Most patients with stage four cancer are not considered candidates for definitive radiotherapy due to the challenge of treating multiple tumors. Our breakthrough technology is challenging that and aims to treat multiple tumors, in parallel, during a single session.
Discover the Potential
Treatment isn’t a one-size-fits-all situation. For many patients, the best treatment plan is a combination of multiple therapies. RefleXion will work together with chemotherapy, immunotherapy and targeted drugs for potentially better outcomes.
Learn About Treatment
By combining PET-CT and radiotherapy, we're able to find and treat cancer using its own emissions.
Discover RefleXion Therapy.
See how RefleXion Therapy can play a role
in your cancer program.
HAYWARD, Calif., and MELBOURNE, Australia, July 8, 2020 – RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a new modality for treating all stages of cancer, and Telix Pharmaceuticals Limited (ASX: TLX), a radiopharmaceutical company developing molecularly-targeted radiation (MTR) products, today announced a strategic collaboration to investigate the clinical utility of combining […]
Please click on the PDF button below to read the complete article:
RefleXion Medical Inc. and Merck & Co., Inc., recently announced their clinical collaboration to evaluate the safety and efficacy of KEYTRUDA® with RefleXion’s biology-guided radiotherapy (BgRT) for treating late-stage cancers. “We believe this exciting collaboration is among one of the first of its kind between an external-beam radiotherapy (EBRT) and a pharmaceutical company,” said Thorsten […]
Let us tell you more.
Contact UsStay up to date.
Sign Up